Surgery Outcome and Adjuvant Chemo-Radiotherapy Response Evaluation in High-grade Glioma with Magnetic Resonance Spectroscopy (MRS)

Document Type : Original Paper

Authors

1 Radiation Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Radiation Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Department of Physiology and Medical Physics, School of Medicine, Baqiyatallah Medical Sciences University, Tehran, Iran

3 School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

4 Radiation Injuries Research Center, Baqiyatallah Medical Sciences University, Tehran, Iran. School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

5 Radiation Injuries Research Center, Baqiyatallah Medical Sciences University, Tehran, Iran

6 Department of Medical Physics, Mashhad University of Medical Sciences, Mashhad, Iran

10.22038/ijmp.2025.82933.2459

Abstract

Introduction: Accurately identifying the remaining tumor extent following glioma near-total or subtotal resection is crucial for determining appropriate treatment options. We aimed to evaluate the surgery outcome and responses to chemoradiation therapy (CRT) in glioma patients with multiparametric magnetic resonance imaging (MRI).
Material and Methods: This prospective study involved 12 patients diagnosed with High-grade glioma. Magnetic resonance spectroscopy (MRS) parameters (Cho/Cr and Cho/NAA) and structural parameters (enhanced lesion volume, non-enhanced lesion volume) were measured to evaluate the surgery outcome with the residual tumor and response to CRT. The imaging process was performed in two stages: once after surgery, before radiotherapy, and once one month after radiotherapy.
Results: The study found that the ROI centers of the Cho/NAA > 1.7 regions had the highest level of agreement and the least separation from the structural ROI. In the case of Cho/Cr, the most significant similarity was seen at a value above 1.5. In the second stage of the study, by comparing metabolic and structural data before and after chemo-radiotherapy treatment, no significant changes in metabolites were observed alongside a substantial decrease in structural parameters in the group with high conformity of structural ROI and metabolic ROI. Still, a significant increase in metabolic ratios was observed in the group with low conformity.
Conclusion: The study's results suggest that employing MRS mapping is a suitable approach for detecting residual tumors and predicting the effectiveness of chemoradiation therapy in glioma patients, in contrast to relying exclusively on conventional MR imaging features.

Keywords

Main Subjects

References

  1. Iuchi T, Sugiyama T, Ohira M, Kageyama H, Yokoi S, Sakaida T, et al. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 2018;35:71– https:// doi. Org/ 10. 1007/s10014- 018- 0309-0.
  2. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery. 2008;62(3):564– discussion 564-76. https:// doi. org/ 10.1227/01.neu.0000317304.31579.17.
  3. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700– author reply 707-8. https:// doi. org/ 10.1227/01.NEU.0000325729.41085.73.
  4. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2009;11(6):842– https:// doi. org/ 10.1215/15228517-2009-005.
  5. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncology: Official J Am Soc Clin Oncol. 2010;28:1963– https:// doi. org/ 10. 1200/ jco. 2009. 26. 3541.
  6. Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology clinical trials. J Clin Oncol. 2017;35:2439– https:// doi. org/ 10. 1200/ jco. 2017. 72. 7511.
  7. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011;13:353– https:// doi. org/ 10. 1093/ neuonc/ noq203.
  8. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan- Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315– https:// doi. org/ 10. 1016/s1470- 2045(17) 30194-8.
  9. Miles KA. Tumour angiogenesis and its relation to contrast enhancementon computed tomography: A review. Eur J Radiol. 1999;30(3):198– https:// doi. org/ 10.1016/S0720-048X(99)00012-1.
  10. Fayed N, Olmos S, Morales H, Modrego PJ. Physical basis of magnetic resonance spectroscopy and its application to central nervous system diseases. Am J Appl Sci. 2006;3(5):1836. https:// doi. org/ 10.3844/ajassp.2006.1836.1845.
  11. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39(1):1– https:// doi. org/ 10.1007/s11064-013-1199-5.
  12. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, et al. 3D MRSI for resected high-grade gliomas before RT: Tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys. 2004;59(1):126– https:// doi. org/10.1016/j.ijrobp.2003.08.023.
  13. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data. Magn Reson Med. 2011;65(1):1– https:// doi. org/ 10.1002/mrm.22579.
  14. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: A randomised, controlled trial. Lancet Oncol. 2011;12(11):997– https:// doi. org/ 10.1016/S1470- 2045(11)70196-6.
  15. Saatchian E, Ehsani S, Montazerabadi A. Evaluation of Two Post-Processing Analysis Methods of Proton Magnetic Resonance Spectroscopy in Glioma Tumors. Journal of Biomedical Physics & Engineering. 2023 Feb;13(1):39.
  16. Roelz R, Strohmaier D, Jabbarli R, Kraeutle R, Egger K, Coenen VA, et al. Residual tumor volume as best outcome predictor in low grade glioma-a nine-years near-randomized survey of surgery vs. biopsy. Sci Rep. 2016;6:32286. https:// doi. org/ 10.1038/srep32286.
  17. Parra NA, Maudsley AA, Gupta RK, Ishkanian F, Huang K, Walker GR, et al. Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes. Int J Radiat Oncol Biol Phys. 2014;90(2):376– https:// doi. org/ 10.1016/j.ijrobp.2014.03.049.
  18. Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, et al. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol. 2016;18(11):1569– https:// doi. org/ 10.1093/neuonc/now100.
  19. Gao W, Wang X, Li F, Shi W, Li H, Zeng Q. Cho/Cr ratio at MR spectroscopy as a biomarker for cellular proliferation activity and prognosis in glioma: Correlation with the expression of minichromosome maintenance protein 2. Acta Radiol. 2019;60(1):106– https:// doi. org/ 10.1177/0284185118770899
  20. Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys. 2001;50(4):915– https:// doi. org/ 10.1016/S0360- 3016(01)01548-6.
  21. Musavi F, Ehsani S, Saatchian E. Application of Multivoxel 1H-Magnetic Resonance Spectroscopy in the Grading of Cerebral Glioma. Iranian Journal of Medical Physics/Majallah-I Fīzīk-I Pizishkī-i Īrān. 2023 Mar 1;20(2).

 

 

Iranian Journal of Medical Physics
Volume 22, Issue 2
March and April 2025
Pages 114-119

Files

History

  • Receive Date: 29 September 2024
  • Revise Date: 30 June 2025
  • Accept Date: 01 July 2025

Share

How to cite

Statistics